People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Akari Therapeutics Plc | — | Biotechnology | Series C | $140.5M | $34.0M | 2012 |
| Advaxis, Inc. | — | Biotechnology | Series A | $53.8M | $3.2M | 2021 |
| Champions Oncology, Inc. | — | Biotechnology | Series A | $36.8M | $506.1M | 2013 |
| Orgenesis Inc. | — | Biotechnology | Series A | $35.2M | $14.4M | 2015 |
| Rosetta Genomics Ltd. | — | Biotechnology | Seed | $8.5M | $77.7M | 2012 |
| Tamir Biotechnology, Inc. | — | Biotechnology | Seed | $8.4M | $35.9M | 2009 |
| Galmed Pharmaceuticals Ltd. | — | Pharmaceuticals | Pre-Seed | $100K | $4.7M | 2017 |
David Sidransky at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Sidransky on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kenneth Berlin | 2 | 2 |
| Tali Yaron-Eldar | 2 | 2 |
| Samir Patel | 1 | 7 |
| Hoyoung Huh | 1 | 7 |
| JAMES HILL | 1 | 6 |
| Chaim Hurvitz | 1 | 6 |
| MARK COHEN | 1 | 5 |
| Thomas Moore | 1 | 5 |
| Paul Weiss | 1 | 5 |
| John Brancaccio | 1 | 5 |
| Paul M. Weiss | 1 | 4 |
| Donald Williams | 1 | 4 |
| Yuval Cohen | 1 | 4 |
| Guy Yachin | 1 | 4 |
| Wendy DiCicco | 1 | 4 |
| Victor Miller | 1 | 4 |
| Richard Berman | 1 | 4 |
| Richard L. Berman | 1 | 3 |
| MARK J. ROSENBLUM | 1 | 3 |
| Johnson Lau | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.